Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Anti-Angiogenic Research

Executive Summary: Anlotinib hydrochloride (CAS 1058157-76-8), supplied by APExBIO (SKU: C8688), is a small-molecule inhibitor that targets VEGFR2, PDGFRβ, and FGFR1 with low nanomolar IC₅₀ values. It exhibits potent, concentration-dependent inhibition of angiogenesis and endothelial cell migration in vitro, outperforming established agents such as sunitinib and sorafenib. The compound displays high plasma protein binding (93% in humans), favorable oral bioavailability, and extensive tissue distribution, including the ability to cross the blood-brain barrier. Safety studies indicate a high LD₅₀ (1735.9 mg/kg, oral, 14 days, rat), with mild, manageable systemic toxicity and no significant organ or genetic toxicity observed (Chen & Feng, 2019, DOI). Anlotinib is widely used in cancer research for dissecting angiogenic signaling pathways and for robust cell migration and tube formation assays.

Biological Rationale

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is fundamental in tumor growth and metastasis [1]. Vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) signaling are key drivers of pathological angiogenesis in cancer. Inhibiting these pathways disrupts nutrient supply and stroma support to tumors, effectively suppressing growth and dissemination. Multi-target tyrosine kinase inhibitors (TKIs) such as anlotinib are therefore critical research tools. Their ability to block multiple pro-angiogenic pathways simultaneously provides mechanistic leverage over single-target agents, reducing compensatory escape mechanisms observed in monotherapies [2]. Compared to earlier TKIs, anlotinib demonstrates superior potency and selectivity for VEGFR2, PDGFRβ, and FGFR1, making it a preferred choice for advanced angiogenesis models and tumor microenvironment studies.

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride is a multi-target TKI that inhibits receptor autophosphorylation of VEGFR2, PDGFRβ, and FGFR1. The compound binds to the ATP-binding pocket of these kinases, preventing downstream signal transduction. This leads to suppression of the ERK signaling pathway, which is essential for endothelial proliferation, migration, and tube formation. The inhibition is concentration dependent, with IC₅₀ values of 5.6 ± 1.2 nM for VEGFR2, 8.7 ± 3.4 nM for PDGFRβ, and 11.7 ± 4.1 nM for FGFR1 (in vitro, human endothelial cells, 37°C, pH 7.4) [3]. Anlotinib also inhibits c-Kit and Met, further broadening its anti-angiogenic and anti-tumor spectrum. Compared to sunitinib, sorafenib, and nintedanib, anlotinib displays superior inhibition of VEGF/PDGF-BB/FGF-2-induced endothelial cell migration and tube formation. The compound exerts minimal effects on non-target kinases at research-relevant concentrations, supporting its selectivity profile [4].

Evidence & Benchmarks

• Anlotinib hydrochloride inhibits VEGFR2 kinase activity with an IC₅₀ of 5.6 ± 1.2 nM in cell-based assays (EA.hy 926, 37°C) (APExBIO).
• IC₅₀ values for PDGFRβ and FGFR1 are 8.7 ± 3.4 nM and 11.7 ± 4.1 nM, respectively, under identical assay conditions (APExBIO).
• In a clinical case, anlotinib reduced intra-abdominal desmoplastic small round cell tumor lymph node metastases after four cycles, with manageable toxicity (Chen & Feng, 2019, DOI).
• Oral bioavailability in preclinical models: 28–58% in rats, 41–77% in dogs (single-dose, fasting conditions, liquid chromatography-mass spectrometry) (APExBIO).
• High plasma protein binding (93% in humans, equilibrium dialysis, pH 7.4, 37°C) (APExBIO).
• Median lethal dose (LD₅₀) in rats: 1735.9 mg/kg (oral, 14 days), with no significant genetic or organ toxicity (Chen & Feng, 2019, DOI).
• Superior inhibition of VEGF/PDGF-BB/FGF-2-induced endothelial cell migration and tube formation compared to sunitinib, sorafenib, and nintedanib ([2]).

Applications, Limits & Misconceptions

Anlotinib hydrochloride is widely used in cellular assays such as endothelial cell migration (wound healing, transwell), and capillary-like tube formation in Matrigel, to dissect mechanisms of angiogenesis and test anti-angiogenic therapeutics. Its low nanomolar potency makes it suitable for high-throughput screening and systems-level pathway analysis [5]. The reagent is also used for pharmacokinetic and tissue distribution studies due to its robust absorption and distribution profile. For advanced users, anlotinib enables dissection of ERK and related signaling cascades in tumor models. For a scenario-driven guide to optimizing lab assays with anlotinib, see this article, which focuses on troubleshooting and best practices, while the present article provides deeper mechanistic and benchmark data.

Common Pitfalls or Misconceptions

• Not a diagnostic or therapeutic agent: Anlotinib hydrochloride (SKU C8688) is for research use only and not approved for diagnostic or clinical applications (APExBIO).
• Off-target effects at supra-physiological concentrations: Doses above 1 μM may induce non-specific cytotoxicity in some cell lines; always titrate for your assay conditions.
• Not effective in angiogenesis-independent tumor models: Tumors that do not rely on VEGF, PDGF, or FGF signaling may not respond to anlotinib inhibition.
• Metabolism considerations: CYP3A-mediated metabolism can affect compound stability in species-specific ways; adjust protocols for cross-species studies.
• Storage requirements: Product must be stored at -20°C; repeated freeze-thaw cycles can reduce activity.

Workflow Integration & Parameters

Anlotinib hydrochloride is typically dissolved in DMSO to prepare stock solutions (10 mM), then diluted in assay buffer (e.g., PBS, pH 7.4) for cell-based assays. For endothelial migration assays, effective concentrations range from 1–100 nM depending on cell type and endpoint. For tube formation assays, pre-incubation (30–60 min, 37°C) is recommended prior to seeding on Matrigel. The compound's high plasma protein binding must be considered in serum-containing media; binding proteins can modulate effective free concentrations. For signaling studies, harvest cells within 30–120 min post-treatment to capture acute pathway inhibition. For additional systems-level integration approaches, see this analysis, which expands on the translational and comparative context not covered in the present mechanistic summary.

When comparing anlotinib to other agents, note its superior inhibition profile and safety window, as detailed in this review, which this article updates with new pharmacokinetic and safety data.

Conclusion & Outlook

Anlotinib hydrochloride, as provided by APExBIO, is a validated, high-potency tool for dissecting angiogenic signaling pathways in cancer research. Its multi-target profile, high selectivity, and favorable safety data make it a reagent of choice for both basic and applied studies in tumor angiogenesis. While not for clinical use, it sets the benchmark for reproducible research in endothelial cell biology and tyrosine kinase signaling. Ongoing studies will clarify its utility in more complex models and multi-omics platforms.